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Abstract Microglia, the resident CNS macrophages, have been implicated in the pathogenesis
of Rett Syndrome (RTT), an X-linked neurodevelopmental disorder. However, the mechanism by
which microglia contribute to the disorder is unclear and recent data suggest that microglia do not
play a causative role. Here, we use the retinogeniculate system to determine if and how microglia
contribute to pathogenesis in a RTT mouse model, the Mecp2 null mouse (Mecp2tm1.1Bird/y). We
demonstrate that microglia contribute to pathogenesis by excessively engulfing, thereby
eliminating, presynaptic inputs at end stages of disease (P56 Mecp2 null mice) concomitant with
synapse loss. Furthermore, loss or gain of Mecp2 expression specifically in microglia (Cx3cr1CreER;
Mecp2fl/yor Cx3cr1CreER; Mecp2LSL/y) had little effect on excessive engulfment, synapse loss, or
phenotypic abnormalities. Taken together, our data suggest that microglia contribute to end
stages of disease by dismantling neural circuits rendered vulnerable by loss of Mecp2 in other CNS
cell types.
DOI: 10.7554/eLife.15224.001
Introduction
Rett Syndrome (RTT) is a devastating, X-linked neurodevelopmental disorder marked by a develop-
mental stagnation and regression in neurological function. Early on these neurological deficits often
have autistic-like features and are accompanied by an array of somatic impairments (Chahrour and
Zoghbi, 2007; Zoghbi, 2003; Lombardi et al., 2015). Since the discovery that mutations in the tran-
scriptional regulator Methyl-CpG-binding protein 2 (Mecp2) underlie the vast majority of RTT cases,
studies in mouse models of RTT have implicated virtually every resident brain cell type (neurons and
glia) in the disorder (Amir et al., 1999; Guy et al., 2011; McGann et al., 2012; Lyst and Bird,
2015; Li, 2012). However, it remains unclear which cell types primarily contribute to each phenotype
and how these vastly different cell types work in concert with each other to initiate and propagate
the disorder.
Microglia, the brain resident myeloid-derived cell, are among the most recent cell types impli-
cated in RTT pathogenesis (Derecki et al., 2012; Cronk et al., 2015; Jin et al., 2015;
Maezawa and Jin, 2010). However, the data have been a subject of increasing controversy
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(Wang et al., 2015). The initial study by Derecki et al. transplanted wild-type (WT) bone marrow
(BM) into an irradiated mouse model of RTT, Mecp2 null mouse (Mecp2-/y(Mecp2tm1.1Jae/y))prior to
phenotypic symptom onset (~4 weeks of age) (Derecki et al., 2012). When WT BM-derived micro-
glia-like cells engrafted the CNS, many RTT-like phenotypes were arrested and lifespan was signifi-
cantly increased. While data suggested that phagocytic activity of microglia may be disrupted in
Mecp2 null mice, it remained unclear precisely how microglia were contributing to the disorder. In a
follow-up study, these data were replicated using a more specific, tamoxifen-inducible Cre driver on
a Mecp2 null background (Cx3cr1CreER; Mecp2lox–stop/y) (Cronk et al., 2015). In addition, RNAseq
analysis revealed abnormalities in glucocorticoid signaling, hypoxia responses, and inflammatory
responses in peripheral macrophages and resident brain microglia isolated from Mecp2 null mice.
While these data support a role for myeloid-derived MeCP2 in RTT phenotypes and pathology,
another recent study demonstrated little to no effect of re-introducing MeCP2 into myeloid cells by
BM chimerism in three different RTT mouse models (Mecp2tm1.1Jae/y, Mecp2LucHyg/y and Mecp2R168X/
y mice), or by genetic expression of MeCP2 in hematopoietic cells (including microglia) in a MeCP2
null background (Vav1-Cre; Mecp2LSL/Y) (Wang et al., 2015). Thus, it remains unclear if and how
microglia, specifically, contribute to pathogenesis.
Recent work in the healthy, developing CNS has demonstrated a surprising new role for microglia
in synaptic circuit remodeling and maturation (Schafer et al., 2013; Tremblay, 2011a;
2011b; Salter and Beggs, 2014). Among the functions at developing synapses, we recently showed
eLife digest Rett Syndrome is a neurodevelopmental disorder with symptoms that typically
begin in girls between 6 and 18 months old. Those affected developmentally stagnate and regress –
during which they lose some of their previously acquired skills and develop an array of physical
impairments.
Mutations in a gene called Mecp2 on the X chromosome cause most cases of Rett Syndrome.
Mice that lack the Mecp2 gene develop symptoms similar to those seen in people with Rett
Syndrome, and so such “Mecp2 null” mice are often used to study the disorder.
Microglia, the resident immune cells of the central nervous system, have been implicated in the
development of Rett Syndrome. Introducing microglia that carry the Mecp2 gene into Mecp2 null
mice has been shown to reduce several disease-associated abnormalities. However, exactly how
microglia contribute to these changes remains unknown. In addition, a more recent report failed to
reproduce these findings, and instead obtained results suggesting that microglia do not affect the
development of Rett syndrome.
Schafer et al. now use the mouse visual system as a model to determine if and how microglia
contribute to the development of Rett Syndrome. Like many other brain regions, the developing
visual system initially has a surplus of connections between neurons, or synapses, which are
subsequently pruned back. Schafer et al. previously showed in the developing visual system of early
postnatal (5 days after birth) control mice (who express the Mecp2 gene) that microglia contribute
to this pruning by engulfing and eliminating a subset of these excessive synaptic connections. The
new experiments by Schafer et al. show that another wave of microglia-mediated synaptic pruning
occurs in 40-day-old juvenile control mice.
Because Mecp2 null mice begin to display features of Rett Syndrome when they’re about 40 days
old, Schafer et al. tested whether the microglia of these animals inappropriately prune synaptic
connections. While this process occurred normally in neonatal and juvenile Mecp2 null mice,
microglia began to excessively engulf cells in Mecp2 null mice when they were around 56 days old.
Unexpectedly, deleting or reintroducing the Mecp2 gene solely in the microglia of these mice had
little effect on pruning activity of the microglia, and failed to affect Rett-syndrome-like symptoms in
the mice.
Taken together, the data presented by Schafer et al. suggest how microglia contribute to the
final stages of Rett Syndrome: by dismantling circuits of neurons that are rendered vulnerable by the
loss of the Mecp2 gene in other cell types.
DOI: 10.7554/eLife.15224.002
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in the retinogeniculate system that microglia contribute to the process of removing excess synapses
by phagocytosing less active or ‘weaker’ presynaptic inputs (Schafer et al., 2012). Importantly, dis-
rupting microglial phagocytic activity resulted in sustained increases in synapse density and connec-
tivity into adulthood. In the current study, we hypothesized that microglia-mediated synaptic
remodeling were abnormal in mouse models of neurodevelopmental disorders associated with aber-
rant brain wiring and chose RTT to test this hypothesis. In many different RTT mouse models, synap-
tic circuit dysfunction can be detected often prior to presentation of significant phenotypic
abnormalities (Zoghbi, 2003; Banerjee et al., 2012; Dani et al., 2005; Dani and Nelson, 2009;
Nguyen et al., 2012; Wood et al., 2009; Noutel et al., 2011; Moretti et al., 2006;
Medrihan et al., 2008). This includes work in the retinogeniculate system where decreases in single
fiber synaptic strength are detected at early stages of disease followed by changes in structural cir-
cuits at late phenotypic stages (Noutel et al., 2011). In addition, studies assessing synapse density
in postmortem human and mouse brain tissue have identified abnormalities, including reductions in
synapse number (Nguyen et al., 2012; Chapleau et al., 2009; Fukuda et al., 2005; Jiang et al.,
2013; Stuss et al., 2012; Xu et al., 2014; Chao et al., 2007).
Here, using the retinogeniculate system, we examined the interactions between microglia and
synapses before, during, and after the onset of phenotypic regression in the MeCP2 null mouse
(Mecp2tm1.1Bird/y) (Guy et al., 2001). Furthermore, we use Cre-lox technology to specifically ablate
or express Mecp2 in microglia and determine whether these cells play a causative role in the struc-
tural and functional synaptic abnormalities. Our data demonstrate that microglia play a role in patho-
genesis of synapses by excessively engulfing presynaptic inputs at end stages of disease in the visual
system; however, this effect is largely secondary and independent of microglia-specific loss of
Mecp2 expression.
Results
Microglia engulf presynaptic inputs during a newly identified wave of
synaptic refinement in the healthy, late-juvenile retinogeniculate
system
The retinogeniculate system, a classic model for studying multiple waves of developmental synapse
refinement, is comprised of retinal ganglion cells (RGCs) residing in the retina that project to relay
neurons in the lateral geniculate nucleus (LGN) of the thalamus (Guido, 2008; Hong and Chen,
2011; Huberman, 2007). We previously established that microglia contribute to early phase synapse
refinement by engulfing, thereby eliminating, presynaptic inputs at P5 (Schafer et al., 2012). Synap-
tic engulfment was subsequently downregulated during later waves of refinement (P9-P30)
(Guido, 2008; Hong and Chen, 2011; Huberman et al., 2008; Torborg and Feller, 2005). It was
unknown whether microglia regulate presynaptic input density after P30. Given that Mecp2 null mice
begin to phenotypically regress P30 and continue regression until premature death ~P60
(Chahrour and Zoghbi, 2007; Guy et al., 2011; Lyst and Bird, 2015; Guy et al., 2001), we first
needed to establish a baseline engulfment in >P30 WT mice.
Recently, a new late wave of refinement was identified between P30 and P60 in which RGC arbors
decrease in size and presynaptic boutons decrease in number (Hong et al., 2014). We hypothesized
that microglia were contributing to this late phase refinement by transiently engulfing synapses
between P30 and P60. We first confirmed a reduction in retinogeniculate synapses in the late, juve-
nile brain of WT mice by immunolabeling P30-P60 LGN with antibodies against the RGC-specific
presynaptic protein vesicular glutamate transporter 2 (VGlut2), and the postsynaptic protein Homer1
(Figure 1—figure supplement 1). There was a significant reduction in the density of RGC-specific
synapses (VGlut2/Homer1-positive) and a reduction in VGlut2-positive terminal size between P30
and P60 (Figure 1—figure supplement 1A–F). This was in contrast to VGlut1-positive corticocortical
synapses, which remain unchanged (Figure 1—figure supplement 1G–I). To determine whether
microglia contribute to late phase synaptic remodeling in the late, juvenile brain and establish a
baseline to assess whether these interactions are disrupted in phenotypic Mecp2 null mice, we next
used our established assay to monitor microglia-synapse interactions in the retinogeniculate system
(Schafer et al., 2012, 2014). One day prior to analysis, RGC inputs were labeled by injection of
anterograde dye into both eyes, cholera toxin conjugated to Alexa dye 594 or 647 (CTB-594 or
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CTB-647), which is resistant to lysosomal degradation. Microglia were labeled by either genetic
expression of EGFP (Cx3CR1EGFP/+ mice) or by immunohistochemistry using an antibody specific to
the microglia-marker, Iba-1. Lysosomes that are specific to and within microglia were labeled with an
antibody against CD68. Similar to previously published work (Schafer et al., 2012), microglia prefer-
entially engulfed RGC inputs within the LGN at P5 (Figure 1—figure supplement 2) compared to
older ages. However, our new data revealed a second wave of engulfment that occurred in the juve-
nile brain specifically at P40, which is downregulated by P50 (Figure 1A–B) and accompanied by a
transient increase in lysosomal content within microglia (Figure 1C). Together with recent work dem-
onstrating decreases in RGC arbor size and bouton numbers between P30 and P60 (Hong et al.,
2014), our work suggests that microglia contribute to this fine-scale refinement by engulfing RGC
presynaptic inputs at P40.
Microglia engulf excessive presynaptic inputs in late phenotypic
Mecp2 null mice
Phenotypic regression is evident in Mecp2 null mice by P40. Furthermore, these abnormalities occur
after the onset of electrophysiological weakening of single fiber synaptic responses in the P20-P30
Mecp2 null retinogeniculate system (Noutel et al., 2011). We hypothesized that microglia-mediated
engulfment of retinogeniculate inputs in P40, juvenile mice was enhanced in Mecp2 null mice with
weakened synapses.
Figure 1. Microglia transiently engulf retinogeniculate presynaptic inputs in the juvenile P40 brain consistent with
late stage synapse refinement. (A) Representative surface rendered microglia (green) and engulfed
retinogeniculate inputs (red) from P30, P40, and P60 LGN. See also Figure 1—figure supplement 2. Grid line
increments = 5 mm. (B) Quantification of engulfment reveals a transient and significant increase in engulfment of
RGC inputs within microglia at P40, an age consistent with late-stage synaptic refinement (Figure 1—figure
supplement 1). (C) Accompanying increased engulfment, microglia also upregulate engulfment capacity at P40 as
measured by lysosomal content within each microglia (CD68 immunoreactivity per cell). *p<0.05, **p<0.01 by one-
way ANOVA, Dunnett’s post hoc test (all ages are compared to P60). All error bars represent SEM; N = 4–6 mice
per age of mixed sex (equal ratios of males and females were used across ages).
DOI: 10.7554/eLife.15224.003
The following figure supplements are available for figure 1:
Figure supplement 1. Refinement of structural synapses in the late juvenile retinogeniculate system.
DOI: 10.7554/eLife.15224.004
Figure supplement 2. Presynaptic input engulfment in early and late phases of synaptic refinement in the
developing retinogeniculate system.
DOI: 10.7554/eLife.15224.005
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Similar to experiments described to assess engulfment in the juvenile WT brain, RGC presynaptic
inputs from both eyes were labeled with CTB-594 or CTB-647 and microglia were labeled by either
genetic expression of EGFP (Cx3CR1 EGFP/+; Mecp2-/y or Cx3CR1EGFP/+; Mecp2+/y) or immunolabel-
ing with anti-Iba-1. In addition, to measure lysosomal content, microglia were labeled with anti-
CD68. Using these methods, we detected no significant difference in microglia-mediated engulf-
ment of retinogeniculate presynaptic inputs in P5-P50 WT or Mecp2 null mice compared to WT lit-
termate controls (Figure 2C). However, in late phenotypic P56-P60 (>P56) Mecp2 null mice, we
found significant increases in engulfed inputs and lysosomal content within microglia processes and
soma compared to WT littermates (Figure 2A–D). Consistent with engulfment being specific to syn-
aptic compartments, we observed no significant RGC death in the retina or LGN (Figure 2—figure
supplement 1) and we observed no changes in engulfment of other neuronal compartments includ-
ing NeuN-positive somas or MAP2-positive dendrites (Figure 2—figure supplement 2). In addition
Figure 2. Microglia excessively engulf retinogeniculate presynaptic inputs in late phenotypic Mecp2 null mice. (A–
B) Representative surface rendered microglia (green) and engulfed RGC inputs (red) demonstrates enhanced
engulfment of presynaptic inputs in P56 (P56-P60) Mecp2 null dLGN (B) as compared to WT littermate controls
(A). Grid line increments = 5 mm. (C) Quantification of engulfment across development reveals excessive
engulfment of presynaptic inputs within P56 Mecp2 null dLGN as compared to WT littermate controls in the
absence of significant RGC cell death (Figure 2—figure supplement 1) or engulfment of other non-synaptic
neuronal debris (Figure 2—figure supplement 2). *p<0.05 by multiple unpaired Student’s t-tests; N = 4–6 mice
per age and genotype; all data are normalized to WT controls at each age. (D) Quantification of lysosomal content
(CD68 immunoreactivity) within microglia in P56 LGN reveals a significant increase in phagocytic capacity in
Mecp2 null mice as compared to WT littermate controls. **p<0.01 by unpaired Student’s t-tests; N = 3 mice per
genotype; data are normalized to WT control. (E–F) There is no significant difference in numbers or volume of
microglia within the P56 LGN by unpaired Student’s t-test; N = 3–5 mice per genotype; data are normalized to
WT control. All error bars represent SEM.
DOI: 10.7554/eLife.15224.006
The following figure supplements are available for figure 2:
Figure supplement 1. There is no significant cell death in the retinas of Mecp2 null mice.
DOI: 10.7554/eLife.15224.007
Figure supplement 2. Engulfment is specific to presynaptic inputs.
DOI: 10.7554/eLife.15224.008
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and in contrast to previously published reports (Cronk et al., 2015; Jin et al., 2015), we observed
no significant changes in morphology (as measured by volume of the cell) or density of microglia,
indexes of the gross, overall reactive state of these cells (Figure 2E–F). However, our analyses were
restricted to microglia within the LGN, a region that was not analyzed previously (Cronk et al.,
2015; Jin et al., 2015). These data demonstrate that, while microglia-mediated waves of synaptic
engulfment are normal in the P5 and P40 Mecp2 null brain, engulfment is excessive in P56 mice—
an age corresponding to late stages of phenotypic regression (Guy et al., 2001). Furthermore, this
timing occurs after significant weakening of single fiber strength at Mecp2 null retinogeniculate syn-
apses (Noutel et al., 2011). These data suggest that microglia do not actively induce circuit defects
in Mecp2 null mice but rather facilitate late stage circuit defects by removing previously weakened
structural synapses.
Retinogeniculate presynaptic terminals and synapses are reduced in
late phenotypic Mecp2 null mice
We next assessed whether increased engulfment in P56-P60 (P56) Mecp2 null mice corresponded
to loss of structural retinogeniculate synapses. We first immunolabeled retinogeniculate presynaptic
terminals in P40 and P56-P60 (P56) Mecp2 null and WT littermate brains with an antibody directed
against VGlut2. While there was no change in the density of VGlut2 immunoreactivity in P40
Mecp2 null mice compared to WT littermate controls, there was a significant decrease at P56, a
time point corresponding to late-stage phenotypic regression in Mecp2 null mice (Figure 3A–D). To
determine whether this reduction in VGlut2 was consistent with a loss of synapses, we further
assessed P56-P60 (P56) Mecp2 null mice for changes in retinogeniculate synapse density defined
as co-localized presynaptic VGlut2 and postsynaptic Homer1 immunoreactivity. Consistent with the
reduction in VGlut2 and excessive synaptic engulfment, there was a significant decrease in retinoge-
niculate synapses in P56-P60 (P56) Mecp2 null mice as compared to WT littermate controls
(Figure 3) and this synapse loss was due to loss of VGlut2-positive terminals (Figure 3C) versus a
decrease in the postsynaptic protein Homer1 (Figure 3H) or RGC cell death (Figure 2—figure sup-
plement 1). Retinogeniculate synapses represent <10% of total synapses within the LGN
(Bickford et al., 2010). To assess the other more abundant excitatory synapses, we immunolabeled
corticogeniculate synapses with an antibody against VGlut1 within the LGN and observed no signifi-
cant difference in the density of these synapses or presynaptic terminals. (Figure 3—figure supple-
ment 1A–E). In addition, we assessed VGlut2 and VGlut1-positive synapse density in a neighboring
thalamic nuclei (medial geniculate nucleus, MGN; Figure 3—figure supplement 1F–G) and
observed no significant loss of these structural synapses. These results demonstrate a specific loss of
retinogeniculate presynaptic terminals in late phenotypic P56 Mecp2 null mice concomitant with
increased microglia-mediated engulfment of presynaptic inputs.
Microglia-specific loss of Mecp2 expression is insufficient to induce
excessive engulfment, synapse loss, or phenotypic regression
To address how loss of Mecp2 expression specifically affects microglia function, we crossed Mecp2fl/
y mice with Cx3cr1CreER mice to conditionally ablate Mecp2 in microglia following tamoxifen injection
(Cronk et al., 2015; Goldmann et al., 2013; Yona et al., 2013). To achieve microglia-specific Mecp2
ablation, tamoxifen was injected at P21-P25 and mice were assessed ~2.5 months later (P110-P120;
Figure 4A; Figure 4—figure supplement 1). Consistent with microglia performing a secondary role,
we found no significant increase in retinogeniculate synapse engulfment or RGC presynaptic terminal
(VGlut2-positive) loss when Mecp2 was ablated specifically in microglia (Cx3cr1CeER/+;Mecp2fl/y Tam,
blue hashed bars) as compared to all control groups (Figure 4B–C).
We also assessed other general phenotypic abnormalities known to be significantly affected in
Mecp2 null animals including overall neurological score, weight loss, rotarod performance and the
optomotor task, an assessment of behavioral visual acuity previously shown to be significantly
decreased in Mecp2 null mice (Figure 4D–G) (Durand et al., 2012). We observed no significant
defects in weight loss or rotarod performance in mice that lacked Mecp2 specifically in microglia
(Cx3cr1CeER/+;Mecp2fl/y Tam, blue hashed bars), as compared to all controls (Figure 4E–F). Neuro-
logical score and optomotor task performance (Figure 4D,G) were also not significantly different
between mice that lacked Mecp2 in microglia (Cx3cr1CreER/+;Mecp2fl/y Tam, blue hashed bars) and
Schafer et al. eLife 2016;5:e15224. DOI: 10.7554/eLife.15224 6 of 19
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Figure 3. Retinogeniculate presynaptic terminals and synapses are reduced in late phenotypic P56 Mecp2 null mice. (A) Immunohistochemistry for
VGlut2 to label retinogeniculate presynaptic terminals, in the dLGN of P40 (A) and P56 (B, P56-P60) Mecp2 wild-type (WT; left column) and null (right
column) littermates. Images are single planes of a confocal z-stack. Scale bar = 20 mm. (C–D) Quantification of RGC presynaptic terminal (VGlut2+
puncta) immunohistochemistry reveals a significant decrease in RGC-specific terminal density (C) and size (D) in P56 Mecp2 null mice (red bars) as
compared to WT littermate controls (grey bars). No significant difference was observed at P40. All data are normalized to WT control for each
age. **p<0.01 unpaired Student’s t-test at each age; N = 3–4 mice per age and genotype; (E–F) Immunohistochemistry for VGlut2 (green) and the
postsynaptic marker Homer1 (in the dLGN of P56 Mecp2 WT (E) and null (F) littermates. Images are single planes from confocal z-stacks. The VGlut2
and Homer1 channels are separated in panels ii–iii. Panels Eiv and Fiv are colocalized VGlut2 and Homer1 puncta. Scale bar = 10 mm. (G–H)
Quantification reveals a a significant decrease in RGC-specific synapses (colocalized VGlut2 and Homer) within the LGN of >P56 Mecp2 null mice (red
bars) as compared to WT littermate controls (grey bars) (G) and no significant change in the density of the postsynaptic protein Homer1 (H). No
significant difference in density was observed in corticogeniculate-specific, VGlut1-positive synapses within the LGN or VGlut2 or VGlut1-containing
synapses within a neighboring thalamice nuceli (Figure 3—figure supplement 1). *p<0.05 by Student’s paired t-test.; N = 5 mice per genotype; all
data are normalized to WT control. All error bars represent SEM.
DOI: 10.7554/eLife.15224.009
The following figure supplement is available for figure 3:
Figure supplement 1. Presynaptic terminal and synapse loss are specific to retinogeniculate synapses.
DOI: 10.7554/eLife.15224.010
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the same genotype treated with oil (Cx3cr1CreER/+;Mecp2fl/y Oil, blue solid bars). However there was
a small but significant effect when compared to WT controls (Cx3cr1CreER/+;Mecp2+/y, gray bars), an
effect which may be confounded by the hypomorphic Mecp2fl/y allele (see Discussion)
(Samaco et al., 2008; Kerr et al., 2008). Together, these data demonstrate that loss of Mecp2 in
microglia is largely insufficient to induce excessive engulfment, synapse loss or phenotypic
abnormalities.
Microglia-specific Mecp2 expression is largely insufficient to attenuate
abnormalities in microglia, synapses, or phenotypes in Mecp2 null mice
In addition to assessing mice that specifically lack Mecp2 expression in microglia, we did the con-
verse experiment using a similar tamoxifen injection paradigm to express Mecp2 specifically in
microglia in an otherwise Mecp2 null background (Cx3cr1CreER/+;Mecp2LSL/y) (Figure 5A, Figure 5—
figure supplement 1). Similar mice have been assessed by other groups and have generated
Figure 4. Excessive engulfment, synapse loss, and phenotypic regression are not induced following microglia-specific loss of Mecp2 expression. (A)
Paradigm for inducing recombination in which mice receive 2 tamoxifen or vehicle (oil) injections 48 hr apart between P21 and P25 (Figure 4—figure
supplement 1). Behavior and postmortem analyses are subsequently performed in P110-P120 mice. (B–C) Quantification of engulfment (B) and VGlut2
terminal density (C) in the LGN of oil (solid bars) or tamoxifen (Tam, hashed bars)-treated mice expressing Cx3cr1CreER/+;Mecp2fl/y (blue bars) or
Cx3cr1CreER/+;Mecp2+/y (grey bars) reveals no significant effect when Mecp2 expression is specifically ablated in microglia (Cx3cr1CreER/+;Mecp2fl/y Tam,
blue hashed bars) compared to all control groups. N = 4–6 mice per genotype (D–G). Quantification of neurological scores, weight loss, latency to fall
from a rotarod, and behavioral visual acuity (optometry) in oil (solid bars) or tamoxifen (Tam, hashed bars)-treated mice expressing Cx3cr1CreER/+;
Mecp2fl/y or Cx3cr1CreER/+;Mecp2+/y. There is no significant difference between mice with Mecp2-deficient microglia (Cx3cr1CreER/+;Mecp2fl/y Tam, blue
hashed bars) versus the same genotype treated with oil (Cx3cr1CreER/+;Mecp2fl/y Oil blue solid bars) in any assays. However, there is a small but
significant deficit in neurological score (D) and visual acuity (G) when comparing mice with Mecp2-deficient microglia (Cx3cr1CreER/+;Mecp2fl/y Tam, blue
hashed bars) to WT controls (Cx3cr1CreER/+;Mecp2+/y, grey bars), an effect likely due to the hypomorphic Mecp2fl/y allele. *p<0.05, **p<0.01 by one-way
ANOVA, Tukey’s post hoc test; N = 7–13 mice per genotype. All error bars represent SEM.
DOI: 10.7554/eLife.15224.011
The following figure supplement is available for figure 4:
Figure supplement 1. Validation of Cre-mediated recombination and Mecp2 deletion in microglia.
DOI: 10.7554/eLife.15224.012
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differing results–one group demonstrated significant attenuation of phenotypes, while another
group observed no effect (Derecki et al., 2012; Cronk et al., 2015; Wang et al., 2015). We sought
to assess microglia dysfunction, synapse loss, and general phenotypes in Cx3cr1CreER/+;Mecp2LSL/y
and clarify these disparate results.
We first assessed whether microglia-specific Mecp2 expression was sufficient to attenuate excess
engulfment and synapse loss in Mecp2 null mice. Similar to P56 Mecp2 null mice, there was a sig-
nificant increase in engulfment and decrease in RGC presynaptic terminal density in late phenotypic
P78-P90 Mecp2LSL/y treated with oil (Cx3cr1CreER/+;Mecp2LSL/y Oil, red solid bars) as compared to
Mecp2+/y controls (grey bars, Figure 5B–C). When Mecp2 was expressed in microglia in a null
Figure 5. Mecp2 expression in microglia is largely insufficient to attenuate excessive engulfment, synapse loss, or phenotypic regression in Mecp2 null
mice. (A) Paradigm for inducing recombination in which mice receive 2 tamoxifen or oil injections 48 hr apart between P21 and P25. Behavior and
postmortem analyses are subsequently performed in P78-P90 mice (Figure 5—figure supplement 1). (B–C) Quantification of engulfment (B) and
VGlut2 terminal density (C) in the LGN of oil (solid bars) or tamoxifen (hashed bars)-treated mice expressing Cx3cr1CreER/+;Mecp2LSL/y (red bars) or
Cx3cr1CreER/+;Mecp2+/y (grey bars). (B) There was a significant decrease in VGlut2 terminal density in mice null for Mecp2 in all cells (red solid bars) and
this effect was attenuated when Mecp2 was expressed in microglia (red hashed bars), an effect which may have resulted from tamoxifen treatment
which induces a trend towards increased VGlut2 density in WT mice (grey hashed bars). *p<0.05, **p<0.01 by one-way ANOVA, Tukey’s post hoc test;
N = 4–6 mice per genotype. (C) In addition, there is a significant increase in engulfment in mice null for Mecp2 in all cells (red solid bars) compared to
WT, oil-treated littermates (grey solid bars) and this effect was not significantly attenuated when Mecp2 was expressed in microglia (red hashed bars).
However, expression of Mecp2 in microglia is no longer significant from controls, which suggests a modest effect. *p<0.05 by one-way ANOVA,
Dunnett’s post hoc test (all genotypes compared to Cx3cr1CreER/+;Mecp2+/y Oil, grey bars; data are not significant by Tukey’s post hoc test); N = 3–5
mice per genotype. All error bars represent SEM. (D–G) Expression of Mecp2 in a null background (red hashed bars) has no significant effect on
attenuation of deficits in neurological score (D) weight loss (E) latency to fall from a rotarod (F) or visual acuity (G) compared to mice null for Mecp2 in
all cells (red bars). However, rotarod performance in Cx3cr1CreER/+;Mecp2LSL/y Tam mice (red hashed bar) was no longer significant from controls (grey
hashed and solid bars), which suggests a modest effect. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA, Tukey’s post hoc test;
N = 6–11 mice per genotype. All error bars represent SEM.
DOI: 10.7554/eLife.15224.013
The following figure supplement is available for figure 5:
Figure supplement 1. Validation of loss or gain of Mecp2 protein in dLGN microglia following Cre-mediated recombination.
DOI: 10.7554/eLife.15224.014
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background (Cx3cr1CreER/+;Mecp2LSL/y Tam, red hashed bars), the excessive engulfment was not
attenuated compared to the same genotype treated with oil (Cx3cr1CreER/+;Mecp2LSL/y Oil, red solid
bars). However, engulfment was no longer significantly different from Mecp2+/y controls (grey solid
and hashed bars), which suggests a modest effect. In contrast, there was a significant enhancement
in RGC terminal density in Cx3cr1CreER/+;Mecp2LSL/y treated with tamoxifen (red hashed bars) com-
pared to null animals (red solid bars; Figure 5C). Tamoxifen administration alone (Cx3cr1CreER/+;
Mecp+/y Tam, grey hashed bars) however, had a trend towards increased VGlut2 density in WT mice
(Figure 5C), which suggests this effect may result from tamoxifen treatment.
We next assessed general phenotypes and behavioral visual acuity in Cx3cr1CreER/+;Mecp2LSL/y
mice. We did not observe a significant improvement in neurological score, weight loss, or visual acu-
ity and only a small improvement in rotarod performance when Mecp2 was specifically expressed in
microglia (Figure 5D–G, Cx3cr1CreER/+;Mecp2LSL/y Tam, red hashed bars). Together with data from
Cx3cr1CreER/+;Mecp2fl/y mice, excessive engulfment, synapse loss, and phenotypic abnormalities are
largely independent of microglia-specific loss or gain of Mecp2 expression. Our data are most con-
sistent with recent reports that microglia-specific Mecp2 expression is insufficient to attenuate phe-
notypes in Mecp2 null mice (Wang et al., 2015).
Discussion
Our results demonstrate that microglia-mediated engulfment of presynaptic inputs is a plastic event
that can be transiently upregulated during multiple waves of synaptic remodeling in the healthy,
developing brain. Furthermore, engulfment of presynaptic inputs is upregulated and excessive in
late phenotypic Mecp2 null mice, concomitant with loss of structural synapses. Cre-lox experiments
demonstrate that microglia-specific loss of Mecp2 expression does not induce excessive engulfment
or synapse loss and, similarly, gain of microglia-specific Mecp2 expression in a null background also
has little effect on attenuation of these parameters. Furthermore, deficits in general phenotypic
abnormalities and behavioral visual acuity are also largely independent of microglia-specific loss or
gain of Mecp2 expression. Along with mice that express Mecp2 specifically in microglia on a null
background, these data offer significant insight into the contribution of these cells to disease pro-
gression. Taken together, our data suggest a model where loss of Mecp2 expression in microglia
has minimal effect on neural circuit integrity and function. Instead, microglia largely respond second-
arily and engulf synapses in response to circuits weakened and rendered vulnerable by loss of
Mecp2 in other resident CNS cell types such as neurons and astrocytes.
Microglia-mediated presynaptic engulfment in the healthy, juvenile
brain
In the process of establishing a baseline of engulfment in the WT juvenile brain, we identified a new
window of microglia-mediated presynaptic engulfment at P40 (Figure 2). This age corresponds to a
newly identified window of late-stage, fine-scale structural synapse elimination in the retinogenicu-
late system (Figure 1—figure supplement 1) (Hong et al., 2014). One open question is what molec-
ular mechanism underlies this late-stage engulfment and, if disrupted, are there sustained deficits in
circuit structure and function.
In early postnatal development (first postnatal week), we previously identified that microglia
engulf presynaptic inputs, in part, through complement-dependent phagocytosis (Schafer et al.,
2012). Mice deficient in the microglial phagocytic receptor, complement receptor 3 (CR3), or com-
plement components C3 and C1q had sustained deficits in engulfment and synaptic remodeling in
the retinogeniculate system (Schafer et al., 2012; Bialas and Stevens, 2013; Stevens et al., 2007).
Furthermore, this process was dependent upon neural activity whereby microglia preferentially
engulfed less active or ‘weaker’ presynaptic inputs. It is unknown whether this late phase presynaptic
input engulfment is dependent upon complement or activity. Given that CR3 and C3 (the ligand for
CR3) decrease over development and C3, in particular, is very low/undetectable in the juvenile brain
(Schafer et al., 2012; Stevens et al., 2007; Stephan et al., 2013), it is likely that another mechanism
underlies microglia-synapse interactions in juvenile animals. It is also clear that this late-stage presyn-
aptic input engulfment is independent of Mecp2, as engulfment at P40 is indistinguishable from WT
littermates (Figure 3C). Future work to assess other molecular pathways underlying microglia-syn-
apse interactions in the juvenile brain will be important going forward.
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Microglia excessively engulf presynaptic inputs in the Mecp2 null brain
While in vitro work has suggested that loss of Mecp2 in microglia can affect glutamate-mediated
neurotoxicity and synapses (Jin et al., 2015; Maezawa and Jin, 2010), it was unknown whether
microglia affect synapses in Mecp2 null mice in vivo. Furthermore, while deficits in glutamatergic,
glucocorticoid, hypoxia, and immune-related pathways have recently been reported in Mecp2 null
microglia (Cronk et al., 2015; Derecki et al., 2012; Jin et al., 2015; Maezawa and Jin, 2010), it
has remained unclear precisely how microglia were contributing to disease on a mechanistic level in
vivo. Our data offer significant insight into these unanswered questions. We demonstrate that micro-
glia excessively engulf presynaptic inputs in the Mecp2 null LGN concomitant with loss of structural
retinogeniculate-specific synapses in the same region. These data are in contrast to previously pub-
lished work that has suggested microglial phagocytic activity is decreased compared to WT mice
(Derecki et al., 2012). However, this discrepancy can be explained by differences in experimental
design used to measure phagocytic activity. Assays used to measure phagocytosis in previous work
were in vitro in response to the addition of UV-irradiated neural precursor cells (Derecki et al.,
2012), a context that is very different from assessing engulfment of presynaptic inputs in the retino-
geniculate system in vivo. In the same study, annexin V was administered in vivo to block phagocytic
activity in Mecp2 null mice with WT BM-derived cells (Mecp2LSL/y/LysmCre), which resulted in failure
of WT BM-derived cells to attenuate phenotypes in Mecp2LSL/y mice. However, it is unclear where
and how annexin V is acting given that phagocytosis was not directly assayed in vivo and the LysmCre
induces expression in many myeloid-derived cell types besides microglia. Indeed, this same group
published findings that loss of Mecp2 primarily affects peripheral myeloid-derived cell numbers and
gene expression early in disease and only later affects microglia (Cronk et al., 2015). Going forward,
it will be important to understand the contribution of these peripheral cell types to disease
phenotypes.
To address whether microglia were primary or secondary to synapse loss, we used Cre-lox tech-
nology to specifically express or ablate Mecp2 in microglia. In doing so, we demonstrate that syn-
apse loss and excessive engulfment in Mecp2 null mice are largely independent of microglial-
specific loss of Mecp2 expression. This is inconsistent with data in which re-expression of Mecp2in
myeloid-derived cells (including microglia) attenuates several behavioral phenotypes and cell loss in
Mecp2 null mice (Derecki et al., 2012; Cronk et al., 2015). However, our data are consistent with
data from this same group suggesting that microglia in Mecp2 null mice are abnormal only in late
phenotypic mice, suggesting a secondary effect (Cronk et al., 2015). Furthermore, our data are con-
sistent with the newest report from a different group that re-expression of Mecp2 in myeloid cells
(including microglia) does not attenuate phenotypes in Mecp2 null or mutant mice (Wang et al.,
2015).
While our data suggest that microglia are largely secondary responders to synapses rendered vul-
nerable by loss of Mecp2 in other CNS cell types, the significance of excessive synaptic engulfment
to disease progression is still unknown. The molecular mechanism driving secondary engulfment of
synapses in Mecp2 null mice and whether modulating this excessive engulfment results in attenua-
tion of synapse loss are also unknown. Complement-dependent phagocytic signaling is one mecha-
nism by which microglia have been shown to engulf synapses in the healthy brain, a pathway which
is also dysregulated in disease (Schafer et al., 2012; Stephan et al., 2012; Chung et al.,
2015; Hong et al., 2016; Lui et al., 2016). In addition, there are a number of other inflammatory
genes that have been identified as dysregulated in Mecp2 null microglia and may contribute to
increased phagocytic activity (Cronk et al., 2015). Finally, we demonstrate that microglia are largely
secondary responders in two mouse models of RTT (Mecp2 null and Mecp2LSL/y). It is still possible
that microglia may be primary initiators of synaptic defects in other RTT models (Mecp2-/+, Mecp2
duplication, Mecp2R270X etc.), a mechanism recently reported in mouse models of frontotemporal
dementia and Alzheimer’s disease (Chahrour and Zoghbi, 2007; Chung et al., 2015; Baker et al.,
2013; Chahrour et al., 2008; Hong et al., 2016; Lui et al., 2016). Assessing microglia function at
synapses in these other disease-relevant models will be important future directions going forward.
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Minimal role for microglia in mediating phenotypic regression in Mecp2
null mice
Ablating Mecp2 expression specifically in microglia had little effect on phenotypic regression (Fig-
ure 4). The minimal effect observed when comparing Cx3cr1CeER/+;Mecp2fl/y tamoxifen-treated mice
to WT controls (Cx3cr1CreER/+;Mecp2+/y) is likely due to the Mecp2fl/y hypomorphic allele. The
Mecp2fl/y mice have reduced Mecp2 expression and develop RTT phenotypes in the absence of Cre-
mediated recombination (Samaco et al., 2008; Kerr et al., 2008), effects which may become appar-
ent if the trajectory of phenotypes were assessed after P120. Similarly, expression of Mecp2 specifi-
cally in microglia in an otherwise null animal (Figure 5) had little to no effect on attenuation of any
phenotype assessed. Together, our data are most consistent with the recent report that WT micro-
glia/myeloid cells have no effect on phenotypes in Mecp2 null or mutant mice but rather phenotypes
are more likely due to loss of Mecp2 expression in other CNS cell types such as neurons or astro-
cytes (Wang et al., 2015; Lioy et al., 2011; Giacometti et al., 2007; Luikenhuis et al., 2004;
Chao et al., 2010; Ito-Ishida et al., 2015). Our data are in contrast to two other reports from
another group that demonstrate introducing Mecp2 in microglia and other myeloid cells on a Mecp2
null background results in significant attenuation of phenotypes (Derecki et al., 2012; Cronk et al.,
2015). The discrepancy may result from difference in paradigms used to express Mecp2. For exam-
ple, in our study, we induced recombination with tamoxifen in Cx3cr1CreER/+;Mecp2LSL/y mice at P21-
P25 and assessed phenotypes at P78. This paradigm results in purely microglia-specific expression
of Mecp2 due to ongoing hematopoiesis that replaces peripheral Mecp2-null cells with WT cells
(Goldmann et al., 2013; Yona et al., 2013). In contrast, Cronk, Derecki et al. induced recombination
in these same mice at 9 weeks (~P63) Cronk et al., 2015. This late tamoxifen administration may be
necessary to observe significant effects on phenotypes and may result from expression of Mecp2 in
peripheral myeloid cells. Furthermore, previous work by this same group demonstrated a significant
attenuation of phenotypic regression in Mecp2 null mice after BM transplantation at P28 and
engraftment with WT myeloid cells by ~P84 or with Cre mediated recombination (LysmCre) in mye-
loid cells from birth Derecki et al., 2012. These paradigms also affect Mecp2 expression in periph-
eral immune cells. Thus, we speculate that these divergent results may be due to differences in
peripheral myeloid-derived cell-specific Mecp2 expression, which is intriguing and worthy of future
investigation. It should also be noted that we did not measure the entire panel of phenotypic abnor-
malities (breathing, open field, etc.) or survival so it is unknown if our results differ in these contexts.
Finally, it is unclear how recently published data using a similar BM chimerism strategy but a differ-
ent Cre mouse (Vav1-Cre) resulted in contradictory results and is also worthy of follow-up investiga-
tion (Wang et al., 2015).
Summary
There have been conflicting reports regarding if and how microglia contribute to phenotypes in
mouse models of RTT (Derecki et al., 2012; Cronk et al., 2015; Wang et al., 2015). Our data offer
significant insight into how microglia contribute to disease in Mecp2 null mice. While microglia-spe-
cific loss of Mecp2 is largely insufficient to induce synapse loss and phenotypic regression and gain
of Mecp2 in expression in Mecp2 null mice is insufficient to attenuate these parameters, microglia
contribute secondarily by dismantling synaptic circuits in complete Mecp2 null mice. Taken together
with previously published data that single fiber strength decreases during early stages of phenotypic
regression in the Mecp2 null retinogeniculate system (Noutel et al., 2011), we propose that micro-
glia dismantle neural circuits in the late phenotypic Mecp2 null brain by engulfing synapses previ-
ously rendered vulnerable and weakened by loss of Mecp2 expression in, most likely, neurons.
Given that recent studies demonstrate the reversibility of circuit defects and phenotypes in RTT
mouse models (Derecki et al., 2012; Lombardi et al., 2015; Lioy et al., 2011; Giacometti et al.,
2007; Luikenhuis et al., 2004; Cronk et al., 2015; Guy et al., 2007; Jugloff et al., 2008;
Castro et al., 2014; Garg et al., 2013; Patrizi et al., 2016; De Filippis et al., 2015; Ma et al.,
2015), identifying a molecular mechanism by which microglia dismantle circuits during late pheno-
typic stages and determining whether this is critical to end-stages of disease will be an important
future directions with therapeutic potential.
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Materials and methods
Animals
Cx3cr1EGFP/+, Ai9 (RCL-tdT), MeCP2-/y (Mecp2tm1.1Bird/y), Mecp2LSL/y (Mecp2tm2Bird/y), and Mecp2fl/y
(Mecptm1Bird/y) mice were obtained from Jackson Labs (Bar Harbor, MA) and Cx3cr1CreER/+ mice
were obtained from Jonathan Kipnis, University of Virginia. All mice were maintained by breeding to
C57BL/6J. For some engulfment experiments, MeCP2-/+ female mice were crossed with male
Cx3cr1EGFP/EGFP mice. For Cre-lox experiments, Mecp2LSL/+ or Mecp2fl/+ female mice were crossed
with male Cx3cr1CreER/CreER mice. All experiments using Cx3cr1EGFP/+ or Cx3cr1CreER/+ mice were
performed with heterozygotes. Unless otherwise noted in figure legend, experiments were per-
formed in male mice. For Cre-lox experiments, P21-P25 Cx3cr1CreER/+-expressing mice were injected
with tamoxifen (20 mg/kg; Sigma Aldrich, Natick,MA) or vehicle (corn oil; Sigma Aldrich, Natick,MA)
subcutaneously two times, 48 hr apart, a protocol previously demonstrated to induce efficient
recombination (Goldmann et al., 2013; Yona et al., 2013). All experiments were approved by insti-
tutional animal use and care committees and performed in accordance with all NIH guidelines for
the humane treatment of animals.
Engulfment analysis
Analysis of engulfment was performed using previously published procedures (Schafer et al.,
2012, 2014). Briefly, both eyes were injected with the same fluorophore-conjugated tracer (either
cholera toxin b subunit conjugated to Alexa dye 594 (CTB-594) or 647 (CTB-647) (Life
Technologies, Carlsbad, CA). Mice were then sacrificed 24 hr later. Brains were fixed in 4% parafor-
maldehyde (PFA; EMS, Hatfield, PA) for 3–4 hrs and 40 mm thick sections were prepared. Sections
were further immonstained with antibodies against Iba-1 (Wako Chemicals, Richmond, VA) and/or
CD68 (AbD Serotec, Raleigh, NC) to measure lysosomal content as previously described
(Schafer et al., 2012). For analysis of non-synaptic material, adjacent brain sections were immunola-
beled with antibodies against Iba-1 (Wako Chemicals, Richmond, VA), NeuN (EMD Millipore, Darm-
stadt, Germany), and MAP2 (EMD Millipore, Darmstadt, Germany). Sections were then imaged on a
UltraView Vox spinning disk confocal microscope equipped with diode lasers (405 nm, 445 nm,
488 nm, 514 nm, 561 nm, and 640 nm) and Volocity image acquisition software (Perkin Elmer, Wal-
tham, MA). Two LGN sections were imaged per animal and 4-63x fields of view were collected from
the dorsal and ventral regions of each dLGN (8 fields of view total per animal). Images were subse-
quently processed in Image J (NIH) and analyzed using Imaris software (Bitplane, Zurich, Switzerland)
as previously described (Schafer et al., 2012, 2014).
Synapse density quantification
Synapses were quantified similar to previously published work with modifications (Schafer et al.,
2012). Briefly, mice were either perfused with 4% PFA followed by a 2 hr drop fix in 4% PFA or fixed
identical to those methods described for engulfment analysis (see above). Tissue sections 15 or 40
mm) were subsequently prepared and immunostained for synaptic proteins. Antibodies included
anti-Homer1 (Synaptic Systems GmbH, Goettingen, Germany), anti-Vesicular Glutamate Transporter
2 (VGlut2; EMD Millipore, Darmstadt, Germany), and anti-VGlut1 (EMD Millipore, Darmstadt, Ger-
many) followed by appropriate, species-specific secondary antibodies conjugated to Alexa dyes (Life
Technologies, Carlsbad, CA). Immunostained sections were imaged with a 63x Zeiss pan-Apochro-
mat oil, 1.4 NA objective on a Zeiss LSM 700 Laser Scanning Confocal equipped with diode lasers
(405, 488, 555 and 633 nm) and Zen image acquisition software (Carl Zeiss, Oberkochen, Germany).
Alternatively, sections were imaged with a Leica SP8 X confocal (Wetzlar, Germany) equipped with
multiple laser lines (405, 458, 488, 496, 514, and 470–670 nm white light) using a HC PL APO 63x/
1.40 oil CS2 or a HC PL APO 40x/1.10 W motCORR (only 40 mm-thick sections) objective and LasX
software. To maintain consistency across animals, the most medial dLGN sections were chosen for
imaging. A total of 3 confocal z-stacks (1 mm spacing) were then collected from dorsal, medial, and
ventral regions of the dLGN section. For each z-stack, (2 confocal planes with the most robust DAPI
staining were subsequently chosen and analyzed for blind analysis using Image J software (NIH,
Bethesda, MD). As a result, a total of 6 single confocal planes were analyzed for each animal. Fluo-
rescent images of pre and/or postsynaptic markers were separated and thresholded blind. Density
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of thresholded pre and/or postsynaptic markers were calculated using the measure particles function
where a puncta size was defined and maintained for all analyses across animals for each marker
(VGlut2 = 0.2-infinity; Homer1 = 0.1-infinity; VGlut1 = 0.1-infinity). The colocalization of puncta was
quantified subsequently using the Image Calculator function applied to thresholded pre and post-
synaptic images. The size and area of each puncta were recorded and then the total puncta area
and average puncta size were calculated for each animal. The synapse or terminal densities were cal-
culated by taking the total puncta area and dividing it by the total area of the field of view. The
puncta density and puncta size were averaged across fields for each animal.
Quantification of cell number and cell death
Samples were prepared and imaged similar to methods described for engulfment and synapse den-
sity quantification (see above). For microglia numbers, 10 x fields of vew were collected and cells
were counted blind using the point tool in Image J. For cell death analysis, retinas were immunola-
beled with antibodies against cleaved caspase 3 (Cell Signaling Technology, Danvers, MA), TUJ1
(BioLegend (formerly Covance) San Diego, CA) or NeuN (EMD Millipore, Darmstadt, Germany),
mounted with media containing DAPI (Vectashield; Vector Labs, Burlingame, CA), and 4 fields of
view (20X) were collected. Cells were counted blind for each field of view using the point tool in
Image J.
Validation of loss or gain of Mecp2 protein by immunohistochemistry
For validation of loss or gain of Mecp2 protein in microglia, a subset of tissue sections collected for
engulfment or synapses analysis were selected and subjected to antigen retrieval using Retrievagen
A (BD Biosciences, San Jose, CA). Briefly, sections were microwaved (power = 2) for 5 min in Retrie-
vagen A solution. This was repeated once and then sections were washed 3 times with 0.1 M phos-
phate buffer. Sections were then immunostained with a rabbit antibody directed against the
C-terminus of Mecp2 (a generous gift from M. Greenberg Harvard Medical School) (Ballas et al.,
2009) and a chicken antibody against Iba-1 (Abcam, Cambridge, MA), overnight at room tempera-
ture. Sections were then washed and HRP-conjugated rabbit and Alexa fluor-conjugated rat antibod-
ies were added to the sections for 1–2 hr at room temperature. Sections were subsequently washed
and an Alexa-fluor conjugated anti-HRP antibody was added overnight at 4 degrees. After the over-
night incubation, sections were mounted and imaged. It should be noted that several other Mecp2
antibodies and staining conditions were attempted, but only this antibody and condition enabled us
to detect Mecp2 protein even in WT microglia. Two 63x fields of view were collected in the lateral,
medial, and ventral portions of the LGN per animal (3 animals per condition) and images were
assessed for Mecp2-positive microglia.
Genomic DNA extraction for validating loss or gain of Mecp2
expression
Sorted cells were lysed and digested in TES buffer (10 mM Tris buffer, pH = 8, 5 mM EDTA, 0.1 M
NaCL, 0.5% SDS and 100 ug PK) overnight in 56˚C. DNA was precipitated in 70% ethanol for 30
mins at room temperature, centrifuged twice at top speed and the tubes were left to dry. Pellets
were reconstituted with TE buffer for subsequent PCR. Genomic PCR for Mecp2 gene was per-
formed using the following primers: 5’-TGGTAAAGA CCCATGTGACCCAAG-3’, 5’-GGC
TTGCCACATGACAAGAC-3’, 5’-TCCACCTAG CCTGCCTGTACTTTG-3’.
Tissue extraction and flow cytometry
Brain samples were harvested from individual mice and tissues were homogenized and incubated
with a HBSS solution containing 2% BSA (Sigma-Aldrich), 1 mg/ml collagenase D (Roche), and 0.15
mg/ml DNase1, filtered through a 70 mm mesh. Homogenized sections were filtered through 80 mM
wire mesh and resuspended in 40% Percoll, prior to density centrifugation (1000 x g. 15 min at 20˚C
with low acceleration and no brake). Cells were acquired on LSRFortessa systems (BD) and analyzed
with FlowJo software (Tree Star). For cell sorting, the FacsAria (BD) was used. Antibodies used
include: CD11b (clone M1/70; AbD Serotec, Raleigh, NC), CD45 (clone 30F11; AbD Serotec,
Raleigh, NC), and MeCP2 (EMD Millipore, Darmstadt, Germany).
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Behavioral visual acuity (optomotor task)
Acuity was measured blind using methods identical to those previously described (Durand et al.,
2012; Prusky et al., 2004).
Rotarod
Rotarod performance was measured blind using methods similar to those previously described
(Derecki et al., 2012; Crawley, 2008). One day prior to training, mice were acclimated to a non-
accelerating rotarod 5 RPM for 5–10 min. The following day, the animals were tested for perfor-
mance (latency to fall) on an accelerating rotarod over 5 trials, which were subsequently averaged to
plot an average latency to fall for each animal.
Neurological scoring
Neurological scores were recorded blind using methods similar to those previously described
(Derecki et al., 2012; Crawley, 2008). Mice were scored on a scale from 0 to 2, with ‘0’ being no
phenotype, and ‘2’ being severe phenotype. For gait, mice were assessed for wide-spread hind
limbs and waddling while locomoting. Hind limb clasping was assessed by suspending mice by the
tail and assessing clenching of hind limbs across the ventral aspect of the body. Tremor was charac-
terized as a visible involuntary shaking and was scored based on the severity. Appearance was
scored based on the presence or lack of grooming and/or hunched posture. The scores were subse-
quently summed to give a neurological score.
Statistical analyses
For all statistical analyses, GraphPad Prism 5 software (La Jolla, CA) was used. Analyses used include
unpaired Student’s t-test, one-way ANOVA, or two-way ANOVA with 95% confidence and appropri-
ate post hoc analyses (indicated in figure legends). All p and N values are indicated in figure
legends. All N’s represent biological replicates (number of mice used for the study). Sample size was
chosen based on our previous work analyzing engulfment and synapse density and work by other
groups assessing phenotypic changes in Mecp2 mutant mice (Derecki et al., 2012; Cronk et al.,
2015; Schafer et al., 2012; Guy et al., 2001; Schafer et al., 2014; Durand et al., 2012; Lioy et al.,
2011; Chao et al., 2010; Guy et al., 2007; Patrizi et al., 2016).
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